...
首页> 外文期刊>Pancreas >Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma.
【24h】

Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma.

机译:MDM2 P1启动子的转录水平升高和低的p53转录水平与人类胰腺导管腺癌的不良预后相关。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTDIVES: Mouse double minute 2 is a key negative regulator of the p53 protein, a central node in the mediation of tumor suppression. The MDM2 gene contains 2 differently regulated promoters, MDM2-P1 and MDM2-P2, which differ strongly in their biological and clinical importance. METHODS: We assess the clinical significance of the expression of messenger RNA (mRNA) transcripts originating from both MDM2 promoters, measured with quantitative reverse transcription polymerase chain reaction in microdissected tissues from 57 patients with pancreatic ductal adenocarcinoma (PDAC). Furthermore, we determine the clinical relevance of p53 mRNA transcript expression and incorporate the somatic p53 mutational status into our analyses. RESULTS: Interestingly, elevated transcript levels from the P1 promoter, but not the P2 promoter, associate significantly with up to 6.3-fold increased relative risk for tumor-related death (Cox multivariate analysis: P = 0.013). Furthermore, transcripts originating from both MDM2 promoters are found to correlate significantly with p53 mRNA levels (up to r = 0.315; P = 0.017). In addition, low p53 mRNA expression associates with worse PDAC prognosis (relative risk = 2.28; P = 0.021). CONCLUSIONS: This study presents the first differentiated analysis of the MDM2-P1, MDM2-P2, and p53 transcript expression in human PDAC and demonstrates the significant clinical implications of those transcripts. Furthermore, it suggests an additional facet in the regulation of MDM2 via its P1 promoter in this malignancy.
机译:目的:小鼠第2分钟2分是p53蛋白的关键负调控因子,p53蛋白是肿瘤抑制介导的中心节点。 MDM2基因包含2个不同调控的启动子,MDM2-P1和MDM2-P2,它们的生物学和临床重要性差异很大。方法:我们通过定量逆转录聚合酶链反应在57例胰腺导管腺癌(PDAC)患者的显微组织中评估了源自两个MDM2启动子的信使RNA(mRNA)转录物的表达的临床意义。此外,我们确定了p53 mRNA转录表达的临床相关性,并将体p53突变状态纳入了我们的分析。结果:有趣的是,P1启动子而不是P2启动子的转录水平升高与肿瘤相关死亡的相对危险性增加多达6.3倍显着相关(Cox多变量分析:P = 0.013)。此外,发现源自两个MDM2启动子的转录物与p53 mRNA水平显着相关(高达r = 0.315; P = 0.017)。此外,低的p53 mRNA表达与较差的PDAC预后相关(相对危险度= 2.28; P = 0.021)。结论:本研究提供了人类PDAC中MDM2-P1,MDM2-P2和p53转录本表达的首次差异分析,并证明了这些转录本的重要临床意义。此外,这表明在该恶性肿瘤中,通过其P1启动子在MDM2的调控中还有其他方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号